SINGAPORE – Travecta Therapeutics, a NYC and Singapore-based biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain-barrier, secured US$15m in Series A funding.
The round was led by TKS1, a life science focused venture capital fund formed by the partnership between SPRIM and Tikehau Capital. The company intends to use the funds to advance the development of TVT-004, its lead non-opioid product targeting pain, to enter clinical trials in 2021, and progress earlier stage research programs in neuro-oncology and neuro-inflammation. Founded by Dr. David Silver and Dr. Mahmood Ahmed together with the SPRIM Ventures team, and led by Dr. Michael Shleifer, CEO, Travecta Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain-barrier. The company’s proprietary platform mVECTATM allows to screen and develop product candidates that can cross the blood-brain barrier targeting novel and untapped neurological pathways. 12/05/2020
